Overview
Insight Economics evaluated claims regarding a motion to enjoin the authorization of a private label version of a biologic drug. The dispute centered around various arguments including the authorization’s impact on irreparable harm, the balance of hardships, and the public interest.  Insight’s work informed an order by the district court denying a motion for a preliminary injunction and the US Court of Appeals for the Third Circuit focusing on arguments regarding irreparable harm.

Challenge
The authorization was similar to previous introductions that would potentially allow for the measurement of potential damages and many factors weighed in favor of the authorization. Insight rebutted an expert report, evaluated literature, utilized research databases, and focused on the case specific fact pattern. Insight considered emerging data from third-party sources and the testimony of additional fact witnesses.  

Results
Insight Economics provided opinions that were heavily relied upon in motions in opposition to the preliminary injunction. The district judge denied the injunction, citing a failure to show Plaintiffs would be irreparably harmed. The Federal Circuit judges questioned that calculating any disruption would be too difficult to measure.